NCT07629258招募中1 期
A First-in-Human Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GW01-200 Tablets in Subjects With Advanced Tumors
Groovy Medicine (Hangzhou) Ltd.4 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2026年7月17日最近更新:
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 100
- 试验地点
- 4
研究概览
简要总结
A phase 1, open-label, first-in-human study mainly aimed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of GW01-200 tablets in participants with advanced tumors, including solid tumors and hematological malignancies.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Documented locally advanced or metastatic solid tumors or advanced hematological malignancies, with disease progression after standard treatment, or intolerant to standard treatment, or no standard treatment is available.
- •Have at least one measurable target lesion.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or
- •Minimum life expectancy ≥ 3 months.
- •Adequate organ and marrow function.
排除标准
- •Participants with a known hypersensitivity to the investigational product(s) or any of the excipients of the product(s).
- •History of other primary malignancies, except for those who have been curatively treated and have no known active disease within 5 years prior to the first dose with a very low potential for recurrence, or adequately treated non-melanoma skin cancer, carcinoma in situ of the cervix, or papillary thyroid cancer with no evidence of disease.
- •Presence of primary central nervous system (CNS) tumors or symptomatic brain metastases; prior or current leptomeningeal disease or spinal cord compression.
- •Radiographic evidence of tumor invasion into major blood vessels (tumor completely approaching, surrounding, or invading the lumen of major blood vessels such as the pulmonary artery or superior vena cava) or evidence of tumor thrombus.
- •Received systemic anti-tumor therapy within 28 days prior to the first dose, including chemotherapy, targeted therapy, anti-angiogenic drugs, biological therapy, immunotherapy, radiotherapy, etc., or received traditional Chinese medicine or herbal medicines with clear anti-tumor effects within 1 week prior to the first dose.
- •Treatment with medications that may affect the metabolism of the investigational drug within 14 days prior to the first dose, such as strong CYP3A inhibitors, strong CYP3A inducers, or P-gp inhibitors.
- •Clinically significant cardiovascular or cerebrovascular diseases within 6 months prior to the first dose of the investigational drug.
- •Known to have active infection, including hepatitis B virus (HBV), hepatitis C virus (HCV), or syphilis.
- •Known history of infection with human immunodeficiency virus (HIV).
- •Active gastrointestinal disease or other condition that will interfere significantly with the swallowing, absorption, distribution, metabolism, or excretion of oral therapy.
- •For female subjects: currently pregnant or lactating.
- •Presence of clinically significant severe ophthalmic examination abnormalities at screening, such as retinitis pigmentosa, maculopathy, active ocular infection, etc., or known history of retinal or optic nerve disorders, such as retinitis pigmentosa, maculopathy, glaucoma, optic neuritis, etc.
- •Participants with a clear bleeding tendency, such as gastrointestinal bleeding, hemorrhagic gastric ulcer, or a history of melena or hematemesis within 2 months before dosing, or those who may experience visceral hemorrhage as determined by the investigator.
- •Clinically symptomatic moderate to severe ascites or pleural effusion, or presence of uncontrolled or moderate to severe pericardial effusion.
研究组 & 干预措施
Ib-Part C
Experimental
Participants with advanced solid tumors will receive GW01-200 tablets at the specified dose.
干预措施: GW01-200 (Drug)
Ia-Part A
Experimental
Participants with advanced solid tumors will receive GW01-200 tablets orally at ascending dose levels.
干预措施: GW01-200 (Drug)
Ib-Part D
Experimental
Participants with relapsed/refractory hematological malignancies will receive GW01-200 tablets at the specified dose.
干预措施: GW01-200 (Drug)
Ia-Part B
Experimental
Participants with relapsed/refractory hematological malignancies will receive GW01-200 tablets orally at ascending dose levels.
干预措施: GW01-200 (Drug)
研究者
研究点 (4)
Loading locations...
相似试验
招募中
1 期
A Phase I Clinical Study of HLX316 in Participants With Advanced/Metastatic Solid TumorsAdvanced/Metastatic Solid TumorsNCT07541534Shanghai Henlius Biotech41
招募中
1 期
A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients With Advanced SCLC or NECNCT07416695Shanghai Henlius Biotech138
招募中
1 期
A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid TumorsNSCLCNCT07274813Shanghai Henlius Biotech254
招募中
1 期
A Phase I Clinical Study to Evaluate the Safety, Tolerability, and PK of HLX48 in Advanced/Metastatic Solid TumorsNCT07473726Shanghai Henlius Biotech72
招募中
1 期
A First-in-human Study of KT502 in Adult Participants With Rheumatoid Arthritis (RA)Rheumatoid Arthritis (RA)NCT07564154Kali Therapeutics, Inc.27